Multi Radiance Medical

Medical Quant USA

Cold Chain Technologies, LLC

Warner-lambert Company

Medical Quant USA Dba Multi Radiance Medical

Douglas Johnson

Max Kanarsky

Larry William Finn

Ian Dwayne Campbell

Jeffrey A Lenk

Michael T Barrett

Scott R Lenk

Ernesto Leal-Junior

Richard M Formato

Gregory E Cook

Richard Orsini

Shreyas S Panse

TzeHo Lee

Fery Pranadi

Mark Fontes

Timothy D Stovall

Karen L Snyder

Joseph Thomas Repine

Andrew David White

Michael Walters

Zhijian Zhu

Ernesto Cesar Pinto Leal-Junior

Ernesto Cesar Pinto Leal, Jr

Gregory Cook

Tzeho Lee

Jerry Clark

Kevin Henegar

David Favor

Lloyd Franklin

Jamie Davis

Brian Nichelson

Ligong Ou

Lorraine Fay

Larry W Finn

Photobiomodulation therapy (PBMT) can be used to improve functional mobility of stroke survivors. A light source device can be contacted to a subject's skin proximal to an area of hemiplegia within a subject due to the stroke. A light signal (with wavelengths from the red to infrared part of the spectrum) can be applied in at least one of a pulsed operating mode, a continuous operating mode, and a super-pulsed operating mode through the light source device to the area of hemiplegia. The light signal is applied for a time sufficient to stimulate a phototherapeutic response in the area of hemiplegia to improve the functional mobility of the subject.

Photobiomodulation therapy to improve functional mobility of stroke survivors

Photobiomedulation therapy (PBMT) can be applied to the eye to treat optical neuritis, a sign of multiple sclerosis (MS). The light of PBMT can be directed into the eye, regardless of the position of the eye, by a device that includes an array of light delivery devices and a heat sink lens. The device can be placed proximal to the eye to direct the light into the eye. The light can have one or more wavelengths from 400-1100 nm and can be applied in at least one of a pulsed operating mode, a continuous operating mode, and a super-pulsed operating mode through the light source device to the skeletal muscle. The light signal is applied for a time sufficient to stimulate a phototherapeutic response in the retina and/or the optic nerve. PBMT applied in this manner provides a noninvasive, safe and effective treatment for optic neuritis.

Photobiomodulation therapy to treat a degenerative condition of the retina and/or the optic nerve

Disorders of the eye can be treated by photobiomodulation therapy according to a device designed to direct light into a patient's eye, no matter the configuration of the eye. The device, including a printed circuit board that includes an array of light delivery devices and a heat sink lens, can be placed proximal to the patient's eye. The light delivery devices can be powered to generate light. The light can be directed into the patient's eye regardless of a position of the patient's eye.

System and method for directing light into a patients eye

Disorders of the eye can be treated by photobiomodulation therapy (PBMT) delivered by a PBMT device. The PBMT device can be configured for placement directly over a patient's eye socket to deliver light into the patient's eye regardless of a position of the patient's eye, while preventing blue light from entering the patient's eye (e.g., due to a filter within the PBMT device and/or an opacity of the housing of the PBMT device). The PBMT device can be powered by a controller.

Reducing light polution in photobiomodulation therapy of a patients eye

Photobiomodulation therapy (PBMT) can be applied to a tender area on a subject's body to treat fibromyalgia. A light source device can be contacted to a subject's skin proximal to a tender area on the subject's body. A light signal (with wavelengths from the red to infrared part of the spectrum) can be applied in at least one of a pulsed operating mode, a continuous operating mode, and a super-pulsed operating mode through the light source device to the tender area. The light signal is applied for a time sufficient to stimulate a phototherapeutic response in the tender area to treat fibromyalgia.

Photobiomodulation therapy to reduce the effects of fibromyalgia

Thermally insulated shipping system for use in transporting a pallet-sized payload. In one embodiment, the system includes a plurality of thermally insulating walls arranged to define an interior volume suitable for receiving a pallet-sized payload. The thermally insulating walls include a top wall, a bottom wall, a front wall, a rear wall, a left wall, and a right wall, of which all but the bottom wall include at least two slots facing towards the interior volume. One of the slots is an inner slot that is more proximal to the interior volume, and one of the slots is an outer slot that is more distal to the interior volume. The system also includes a plurality of inner cassettes disposed in at least some of the inner slots and a plurality of outer cassettes disposed in at least some of the outer slots. The inner and outer cassettes include phase-change materials.

Thermally insulated shipping system for pallet-sized payload, methods of making and using the same, and kit for use therein

Photobiomodulation therapy (PBMT) can be applied to a dystrophic muscle to delay dystrophy progression. A light source device can be contacted to a subject's skin proximal to a dystrophic muscle or muscle group. A light signal (with wavelengths from the red to infrared part of the spectrum) can be applied in at least one of a pulsed operating mode, a continuous operating mode, and a super-pulsed operating mode through the light source device to the dystrophic muscle or muscle group. The light signal is applied for a time sufficient to stimulate a phototherapeutic response in the dystrophic muscle or muscle group.

Photobiomodulation therapy to delay dystrophy progression

Photobiomodulation therapy (PBMT) provides an effective, non-invasive treatment for urinary incontinence that can be used discretely. A light source device can be contacted to a subject's skin proximal to a subject's bladder. A light signal can be applied in at least one of a pulsed operating mode, a continuous operating mode, and a super-pulsed operating mode through the light source device to the subject's skin proximal to the subject's bladder. The light signal can be applied for a time sufficient to stimulate a phototherapeutic response in one or more muscles and/or nerves proximal to the bladder to treat urinary incontinence.

Photobiomodulation therapy for urinary incontinence

Respiratory function can be preserved in patients requiring mechanical ventilation (MV), such as patients with severe COVID-19, using a photoceutical applied by a photoceutical medical device (including at least one super pulsed laser to provide superpulsed light of a first wavelength, at least two non-coherent light sources to provide light of a second wavelength, and at least two other non-coherent light sources to provide light of a third wavelength) to at least one inspiratory muscle. The photoceutical includes a combination of superpulsed light of the first wavelength, light of the second wavelength, and light of the third wavelength. At least two sites on the body of the patient can be selected and the photoceutical can be delivered: at one of the sites for a first time period; and at another of the sites for a second time period.

System and method for treating patients requiring mechanical ventilation

Eye patch device

Brain dysfunction can be treated by restructuring neural pathways in the brain. A desired area in the brain to form a new neural pathway is selected. The area receives a sequential combination of (1) transcranial photobiomodulation therapy (PBMT) including a series of pulses having a frequency matched to a target brain wave and (2) another transcranial stimulation (e.g., transcranial direct current electrical stimulation and/or transcranial magnetic stimulation). The different stimulation mechanisms ensure that neuroplasticity occurs to restructure a neural pathway that is dysfunctional in nature to a new neural pathway that conducts normally.

Restructuring neural pathways in the brain with a combination of transcranial therapies

Growing community of inventors

Brownstown, MI, United States of America

Douglas Johnson